Successful Genome Editing in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC)

4 April 2022, Zwingenberg (Germany) - BRAIN Biotech AG has achieved a major milestone successfully demonstrating genome editing in mammalian cell lines with its proprietary CRISPR-Cas genome editing nucleases BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC).